An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Aptinyx to Participate in 2021 Cantor Virtual Global Healthcare Conference
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Aptinyx Inc. (NASDAQ: APTX), a clinical-stage biopharmaceutical company, will have CEO Norbert Riedel participate in a fireside chat at the 2021 Cantor Virtual Global Healthcare Conference on September 30, 2021, at 10:00 a.m. ET. A live webcast of the event will be available on the ‘Events and Presentations’ page on Aptinyx's website and archived for 30 days. Aptinyx specializes in developing therapies for brain and nervous system disorders, with three clinical candidates addressing chronic pain, PTSD, and cognitive impairment.
Positive
None.
Negative
None.
EVANSTON, Ill.--(BUSINESS WIRE)--
Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that Norbert Riedel, Ph.D., chief executive officer, will participate in a fireside chat at the 2021 Cantor Virtual Global Healthcare Conference on September 30, 2021 at 10:00 a.m. ET.
A live webcast of the presentation will be available to view on the “Events and Presentations” page in the “Investors & Media” section of Aptinyx’s website at https://ir.aptinyx.com and will be archived on Aptinyx’s website for 30 days following the event.
About Aptinyx
Aptinyx Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of proprietary synthetic small molecules for the treatment of brain and nervous system disorders. Aptinyx has a platform for discovery of novel compounds that work through a unique mechanism to modulate—rather than block or over-activate—NMDA receptors and enhance synaptic plasticity, the foundation of neural cell communication. The company has three product candidates in clinical development in central nervous system indications, including chronic pain, post-traumatic stress disorder, and cognitive impairment. Aptinyx is also advancing additional compounds from its proprietary discovery platform, which continues to generate a rich and diverse pipeline of small-molecule NMDA receptor modulators with the potential to treat an array of neurologic disorders. For more information, visit www.aptinyx.com or follow Aptinyx on Twitter @Aptinyx.
When will Aptinyx participate in the Cantor Virtual Global Healthcare Conference?
Aptinyx will participate in the 2021 Cantor Virtual Global Healthcare Conference on September 30, 2021, at 10:00 a.m. ET.
How can I watch the Aptinyx presentation at the conference?
You can watch the live webcast of the Aptinyx presentation on their 'Events and Presentations' page on their website.
What is the focus of Aptinyx's research and development?
Aptinyx focuses on developing transformative therapies for brain and nervous system disorders, with candidates for chronic pain, PTSD, and cognitive impairment.
What is Aptinyx's stock symbol?
Aptinyx's stock symbol is APTX.
Where can I find more information about Aptinyx?
More information about Aptinyx can be found on their official website at www.aptinyx.com.
